Rhoen Klinikum AG (RHKG)

Vienna


	Symbol		Exchange		Currency
	RHKG		Xetra		EUR	Delayed
	RKAGY		OTC Markets		USD	Delayed
	0NQH		London		EUR	Real-time
	RHKG		TradeGate		EUR	Delayed
	RHKG		Frankfurt		EUR	Delayed
	RHKG		Vienna		EUR	Real-time

Currency in EUR

Disclaimer

12.700

0.000(0.00%)

Real-time Data11/10

Fair Value

Day's Range

12.700

12.700

52 wk Range

9.650

13.300

RHKG Income Statement

Featured here, the Income Statement (earnings report) for Rhoen Klinikum AG, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

1,480.94

1,546.06

1,591.21

1,661.16

1,734.73

Total Revenues Growth

+6.51%

+4.4%

+2.92%

+4.4%

+4.43%

Cost Of Revenues

1,329.2

1,387.04

1,408.58

1,457.38

1,531.85

Gross Profit

151.74

159.02

182.63

203.78

202.88

Gross Profit Growth

-8.76%

+4.8%

+14.84%

+11.58%

-0.44%

Gross Profit Margin %

10.25%

10.29%

11.48%

12.27%

11.69%

Other Operating Expenses, Total

134.08

151.7

154.91

172.47

163.88

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+6.35%	+13.14%	+2.12%	+11.33%	-4.98%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	4.2	3.82	3.8	4.3	4.8
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	61.36	78.25	80.47	98.63	93.59

Operating Income

17.66

7.33

27.72

31.31

39

Operating Income Growth

-56.1%

-58.49%

+278.21%

+12.96%

+24.55%

EBIT Margin %

1.19%

0.47%

1.74%

1.88%

2.25%

Net Interest Expenses

-2.8

-6.6

-2.7

-2.8

6.8

Net Interest Expenses Growth

-59.27%

-135.71%

+59.09%

-3.7%

+342.86%

Interest Expense, Total

-3

-7.4

-3.2

-4.1

-3.7

Interest And Investment Income

0.2

0.8

0.5

1.3

10.5

Other Non Operating Expenses, Total

2.2

1.13

1.29

2.12

2.23

EBT, Excl. Unusual Items

17.05

1.85

26.31

30.63

48.03

Gain (Loss) On Sale Of Assets

-0.1

-1.03

-0.1

-0.2

-0.3

Other Unusual Items, Total

37.3

3.3

1.7

3.2

-

EBT, Incl. Unusual Items

54.24

3.93

27.36

33.63

47.73

EBT, Incl. Unusual Items Growth

-14.14%

-92.75%

+595.85%

+22.91%

+41.93%

EBT, Incl. Unusual Items Margin

3.66%

0.25%

1.72%

2.02%

2.75%

Income Tax Expense

9.76

1.47

-2.87

6.69

7.56

Net Income to Company

44.48

2.46

30.23

26.94

40.17

Minority Interest

-1.2

-1.01

-1.93

-1.8

-1.46

Net Income

43.28

1.45

28.3

25.14

38.71

Net Income Growth

-11.67%

-96.65%

+1,850.03%

-11.14%

+53.96%

Net Income Margin %

2.92%

0.09%

1.78%

1.51%

2.23%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

43.28

1.45

28.3

25.14

38.71

Basic EPS - Continuing Operations

0.65

0.02

0.42

0.38

0.58

Basic EPS - Continuing Operations Growth

-11.67%

-96.65%

+1,850.1%

-11.14%

+53.96%

Diluted EPS - Continuing Operations

0.65

0.02

0.42

0.38

0.58

Diluted EPS - Continuing Operations Growth

-11.44%

-96.91%

+2,000%

-10.56%

+53.96%

Basic Weighted Average Shares Outstanding

66.94

66.94

66.94

66.94

66.94

Diluted Weighted Average Shares Outstanding

66.94

66.94

66.94

66.94

66.94

Dividend Per Share

-

-

-

0.15

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

82.96

73.73

94.82

97.61

101.5

EBITDA Growth

-16.73%

-11.12%

+28.6%

+2.95%

+3.98%

EBITDA Margin %

5.6%

4.77%

5.96%

5.88%

5.85%

EBIT